Контроль частоты сердечных сокращений обеспечивает дополнительные преимущества в лечении больных стабильной ишемической болезнью сердца

1. Fox K, Purcell H, Pepper J, et al. Management of angina pectoris. In: Camm J.A, Luscher T.F., Serruys P.W. Cardiovascular Medicine. Blackwell Publishing 2006; 425-52.

2. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341-81.

3. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.

4. Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; 10: 45-50.

5. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.

6. Palatini P, Benetos A, Grassi G, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-10.

7. Graham L, Atar D, Borch-sohnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J dol:10.1093/eurheartj/ehm316, 2007.

8. Комитет экспертов ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации. Приложение. Кардиоваск тер профил 2004.

9. ACC/AHA 2002 Guideline Update for the management of patients with Chronic Stable angina. Am Heart J 2002.

10. Fox K, Ferrari R, Tendera M, et al., on behalf of the BEAUTIFUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study. Am Heart J 2006; 152: 860-6.